Cargando…
BAP31, a promising target for the immunotherapy of malignant melanomas
PURPOSE: Malignant melanoma’s (MM) incidence is rising faster than that of any other cancer in the US and the overall survival at 5 years is less than 10%. B cell associated protein 31 (BAP31) is overexpressed in most MMs and might be a promising target for immunotherapy of this disease. EXPERIMENTA...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405826/ https://www.ncbi.nlm.nih.gov/pubmed/25903101 http://dx.doi.org/10.1186/s13046-015-0153-6 |
_version_ | 1782367668292026368 |
---|---|
author | Yu, Shaojuan Wang, Fuli Fan, Li Wei, Yuying Li, Haitao Sun, Yuanjie Yang, Angang Jin, Boquan Song, Chaojun Yang, Kun |
author_facet | Yu, Shaojuan Wang, Fuli Fan, Li Wei, Yuying Li, Haitao Sun, Yuanjie Yang, Angang Jin, Boquan Song, Chaojun Yang, Kun |
author_sort | Yu, Shaojuan |
collection | PubMed |
description | PURPOSE: Malignant melanoma’s (MM) incidence is rising faster than that of any other cancer in the US and the overall survival at 5 years is less than 10%. B cell associated protein 31 (BAP31) is overexpressed in most MMs and might be a promising target for immunotherapy of this disease. EXPERIMENTAL DESIGN: Firstly, we investigated the expression profiles of human BAP31 (hBAP31) and mouse BAP31 (mBAP31) in human and mouse normal tissues, respectively. The expression level of hBAP31 in human MMs and mBAP31 in B16 melanoma cells was also analyzed. Then we constructed novel mBAP31 DNA vaccines and tested there ability to stimulate mBAP31-specific immune responses and antitumor immunity in B16 melanoma-bearing mice. RESULTS: For the first time, we found that protein expression of hBAP31 were dramatically upregulated in human MMs when compared with human normal tissues. Predominant protein expression of mBAP31 was found in mouse B16 melanoma cells but not in mouse important organs. When mice were immunized with mBAP31 DNA vaccines, strong cellular response to mBAP31 was observed in the vaccinated mice. CTLs isolated from immunized mice could effectively kill mBAP31-positive target mouse B16 melanoma tumor cells in vitro and vaccination with mBAP31 DNA vaccines had potent anti-tumor activity in therapeutic model using B16 melanoma cells. CONCLUSIONS: These are the first data supporting a vaccine targeting BAP31 that is capable of inducing effective immunity against BAP31-expressing MMs and will be applicable to human MMs and hBAP31 DNA vaccine warrants investigation in human clinical trials. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13046-015-0153-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4405826 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44058262015-04-23 BAP31, a promising target for the immunotherapy of malignant melanomas Yu, Shaojuan Wang, Fuli Fan, Li Wei, Yuying Li, Haitao Sun, Yuanjie Yang, Angang Jin, Boquan Song, Chaojun Yang, Kun J Exp Clin Cancer Res Research Article PURPOSE: Malignant melanoma’s (MM) incidence is rising faster than that of any other cancer in the US and the overall survival at 5 years is less than 10%. B cell associated protein 31 (BAP31) is overexpressed in most MMs and might be a promising target for immunotherapy of this disease. EXPERIMENTAL DESIGN: Firstly, we investigated the expression profiles of human BAP31 (hBAP31) and mouse BAP31 (mBAP31) in human and mouse normal tissues, respectively. The expression level of hBAP31 in human MMs and mBAP31 in B16 melanoma cells was also analyzed. Then we constructed novel mBAP31 DNA vaccines and tested there ability to stimulate mBAP31-specific immune responses and antitumor immunity in B16 melanoma-bearing mice. RESULTS: For the first time, we found that protein expression of hBAP31 were dramatically upregulated in human MMs when compared with human normal tissues. Predominant protein expression of mBAP31 was found in mouse B16 melanoma cells but not in mouse important organs. When mice were immunized with mBAP31 DNA vaccines, strong cellular response to mBAP31 was observed in the vaccinated mice. CTLs isolated from immunized mice could effectively kill mBAP31-positive target mouse B16 melanoma tumor cells in vitro and vaccination with mBAP31 DNA vaccines had potent anti-tumor activity in therapeutic model using B16 melanoma cells. CONCLUSIONS: These are the first data supporting a vaccine targeting BAP31 that is capable of inducing effective immunity against BAP31-expressing MMs and will be applicable to human MMs and hBAP31 DNA vaccine warrants investigation in human clinical trials. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13046-015-0153-6) contains supplementary material, which is available to authorized users. BioMed Central 2015-04-18 /pmc/articles/PMC4405826/ /pubmed/25903101 http://dx.doi.org/10.1186/s13046-015-0153-6 Text en © Yu et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Yu, Shaojuan Wang, Fuli Fan, Li Wei, Yuying Li, Haitao Sun, Yuanjie Yang, Angang Jin, Boquan Song, Chaojun Yang, Kun BAP31, a promising target for the immunotherapy of malignant melanomas |
title | BAP31, a promising target for the immunotherapy of malignant melanomas |
title_full | BAP31, a promising target for the immunotherapy of malignant melanomas |
title_fullStr | BAP31, a promising target for the immunotherapy of malignant melanomas |
title_full_unstemmed | BAP31, a promising target for the immunotherapy of malignant melanomas |
title_short | BAP31, a promising target for the immunotherapy of malignant melanomas |
title_sort | bap31, a promising target for the immunotherapy of malignant melanomas |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405826/ https://www.ncbi.nlm.nih.gov/pubmed/25903101 http://dx.doi.org/10.1186/s13046-015-0153-6 |
work_keys_str_mv | AT yushaojuan bap31apromisingtargetfortheimmunotherapyofmalignantmelanomas AT wangfuli bap31apromisingtargetfortheimmunotherapyofmalignantmelanomas AT fanli bap31apromisingtargetfortheimmunotherapyofmalignantmelanomas AT weiyuying bap31apromisingtargetfortheimmunotherapyofmalignantmelanomas AT lihaitao bap31apromisingtargetfortheimmunotherapyofmalignantmelanomas AT sunyuanjie bap31apromisingtargetfortheimmunotherapyofmalignantmelanomas AT yangangang bap31apromisingtargetfortheimmunotherapyofmalignantmelanomas AT jinboquan bap31apromisingtargetfortheimmunotherapyofmalignantmelanomas AT songchaojun bap31apromisingtargetfortheimmunotherapyofmalignantmelanomas AT yangkun bap31apromisingtargetfortheimmunotherapyofmalignantmelanomas |